drugset / Trial / NCT00005023

Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer

NCT00005023

Phase 1 Completed University of Washington
Treatment

Summary

RATIONALE: Vaccines may make the body build an immune response to tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy plus sargramostim in treating patients who have stage III or stage IV cancer.

Timeline

Start
1999-03
Primary completion
2001-01
Completion
2001-01

Drugs

EvaluationDrugModalityDoseRoute
Subject HER-2/neu peptide vaccine Vaccine Intravenous
Background sargramostim Protein / enzyme biologic